Download NIH Modular Budget Justification Sample (None of the names used

NIH Modular Budget Justification Sample
(None of the names used here is real; please do not infer them to anyone in reality.)
Personnel Scott Smart, Ph.D., Principal Investigator (2.4 calendar months per year) will be involved in the conception,
design, and supervision of all experiments in this project. Dr. Smart has significant experience in protein chemistry and
molecular virological techniques including virus culture, titering, genetic manipulation, recombinant virus constructions,
and evaluation of virus infectivity. He will train all personnel in his laboratory in the techniques of cellular and molecular
virology, including those related to the major assays used (including handling of HHV-8 and derivative variants). Dr.
Smart will oversee the execution and interpretation of all data generated by all members of the research group. He will
perform some of the experiments and will be available to assist in interpretation of all data generated. He will write and/or
edit all manuscripts resulting from this project. Dr. Smart will also present data at conferences intensive to basic cancer
research, but he will also seek to disseminate new findings at conferences of broad interest to molecular cancer biologists
in general. Dr. Smart is a U.S. Department of Defense Employee, so no salary compensation will be requested to
support his efforts on this project.
Just Wright, Graduate Medical Research Assistant (12.0 calendar months per year) is an M.D./Ph.D. student in the
Emerging Infectious Diseases Program of the USUHS Department of Microbiology and Immunology. He will work
alongside the post-doctoral Fellow on several aspects of this project, particularly those involving culture and derivation of
prostate cancer cell lines. Mr. Wright already has a solid working knowledge of many of the cell lines that will be used for
this study and has generated all the preliminary data that are driving this research. Mr. Wright stipend is provided by the
USUHS School of Medicine, so no salary is requested for him from this grant.
TBD, Postdoctoral Fellow (12.0 calendar months per year), will be responsible for cultivation of recombinant HHV-8,
development of cell culture assays involving immunofluorescence (IFA) as well as transcriptional profiling of gene
expression using real-time and quantitative PCR, generating new cell lines expressing a variety of cellular molecules
predicted to play a role in the inflammatory axis in order to study them in isolation. The fellow will be encouraged to write
manuscripts based on novel findings from the proposed work. This individual will be hired as a Henry M. Jackson
Foundation employee and compensation is requested.
Collaborators/Consultants
Able Collab, Ph.D., Collaborator (0.12 calendar months). Dr. Collab is Assistant Director of the Basic Science Research
Program, and Research Assistant Professor of Surgery. He is the Chief of the Section for Gene Regulation and
Bioinformatics. His expertise is in the regulation, expression and functions of prostate cancer-associated genes such
as PMEPA1, ERG and androgen-regulated genes. His current work focuses on determining the relationship between
oncogenic processes and androgen receptor signaling, as well as developing new approaches towards the treatment of
prostate cancer by synergizing state-of-the-art molecular and in silico bioinformatic methodologies. He is the recipient of
the prestigious CaP Foundation Competitive Award, and an award from the Congressionally Directed Medical Research
Program. Specifically, Dr. Collab will assist in setting up a transcriptome profiling platform along with the Post-doctoral
fellow. He will also serve as a liaison with the Historically black colleges and University (HBCU) consortium as part of
an effort to seed a Health Disparities component derived from this proposal, which involves looking at differential
susceptibility to HHV-8 infection as one of the risk factors for inflammatory prostatitis.
FY 2014 Indirect Costs and Fringe Benefit Rates:
* The fringe rate used is 33.43% for Tier 1 employees and 3.60% for Tier 2 employees (all employees in this
proposal are Tier 1).
HJF indirect cost (IDC) is calculated based on the value-added cost base overhead rates. The 36.48% of USU on-site
rate is applied on for all allowable direct cost, less sub-award costs; additional 14.30% of Company-wide G&A rate is
applied on the total direct cost less sub-award. For proposals including subawards, additional 1.23% is applied on total
sub-award costs. These fringe benefit and indirect cost rates were proposed to U.S. Army Medical Research Acquisition
Activity as provisional rates on 9/16/2013.